RxDoctor Payments Data

Angela Lebeter

Family · Highland, INNPI 1144895418

Payments from drug & device makers

$851in general payments, 2019–2025

Across 28 payments — averaging $30.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$192
  • Mirati Therapeutics, Inc.$121
  • E.r. Squibb & Sons, L.L.C.$116
  • Inari Medical, Inc.$94
  • Xeris Pharmaceuticals, Inc.$65
  • Boehringer Ingelheim$51
  • plus $211 from 8 others

What the payments were for

  • Food & beverage$851100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$851 in reported general payments places this provider in the 60th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$11,170
Medicare patients
72
Services billed
227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$40,300
EliquisApixaban40$26,442
XareltoRivaroxaban15$17,995
MounjaroTirzepatide13$15,971
JanuviaSitagliptin Phosphate18$15,244
LinzessLinaclotide26$14,082
Combivent RespimatIpratropium/Albuterol Sulfate15$6,966
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$5,129
Humalog Kwikpen U-100Insulin Lispro15$3,415
Insulin Aspart FlexpenInsulin Aspart13$1,789
Pantoprazole Sodium94$1,283
Albuterol Sulfate HfaAlbuterol Sulfate58$1,215
Atorvastatin Calcium157$1,003
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$900
Levothyroxine Sodium82$858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$29$40,30031 claims
Johnson & JohnsonXarelto$12$17,99515 claims
Lilly USA, LLCMounjaro$25$15,97113 claims
AbbVieLinzess$51$14,08226 claims
Boehringer IngelheimCombivent Respimat$51$6,96615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,392 family providers in Indiana.

Other family in Highland

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →